NCT05566574

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

RP-3500 (ATRi) + External Beam Radiotherapy (EBRT) for the Palliative Treatment of Metastatic Disease

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.

Conditions

• Solid Tumor
• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	RP-3500	RP-3500 on Days 1-5.
RADIATION	External Beam Radiotherapy (EBRT)	Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5

Timeline

• Start date: 2022-09-30
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2022-10-04
• Last updated: 2025-12-17

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study